Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256008 | 0.82 | HSD11B1 (0.48) | CASP1METAP2MAOBALDH1A1NPC1 | |
| SCHEMBL3152568 | 0.78 | KDM4E (0.42) | METAP2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29664672 | 0.78 | RAB9A (0.52) | MAOBALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL928222 | 0.78 | METAP2 (0.39) | METAP2MAOBALDH1A1NPC1RAB9A | |
| SCHEMBL13458074 | 0.78 | SMN1; SMN2 (0.47) | CASP1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1686039 | 0.78 | RAB9A (0.52) | MAOBALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2314305 | 0.78 | MAPT (0.45) | MAOBALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30402035 | 0.77 | RAB9A (0.50) | CASP1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL240423 | 0.77 | RAB9A (0.50) | CASP1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29664429 | 0.76 | LMNA (0.43) | CASP1ALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1651615-B1 | PYRIDAZINYL- PIPERAZINES AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| CN-100584831-C | Pyridazinyl-piperazines and as the application of histamine H 3 receptor ligands | NOVO NORDISK AS | 2010-01-27 | — | — | CN | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| CN-101238121-A | Fused bicyclic heterocycle substituted quinuclidine derivatives | ABBOTT LAB (US) | 2008-08-06 | — | — | CN | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| CN-101189233-A | Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor | ABBOTT LAB (US) | 2008-05-28 | — | — | CN | disclosed |
| WO-2005066166-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005009976-A1 | PYRIDAZINYL- PIPERAZINES AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
| CN-1075477-A | N-cyanopyridazinones having herbicidal activity | AGROLINZ AGRARCHEMIKALIEN (AT) | 1993-08-25 | — | — | CN | disclosed |
| US-4515791-A | Substituted phenyl-1,2,4-triazolo[2,3-b]pyridazin-3(2H)ones as anti-asthma agents | AMERICAN CYANAMID COMPANY (US) | 1985-05-07 | — | — | US | disclosed |
| US-4117130-A | 6-PHENYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZINES | AMERICAN CYANAMID COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4112095-A | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4092311-A | Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates | AMERICAN CYANAMID COMPANY (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CASP1 2474/4885ADORA2A 51/4885ADORA1 56/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | CASP1 2535/4885ADORA2A 58/4885ADORA1 54/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | CASP1 2456/4885ADORA2A 58/4885ADORA1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.